PMID- 27845341
OWN - NLM
STAT- MEDLINE
DCOM- 20170620
LR  - 20220330
IS  - 1572-0241 (Electronic)
IS  - 0002-9270 (Linking)
VI  - 112
IP  - 1
DP  - 2017 Jan
TI  - Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone 
      Strength and Structure.
PG  - 95-101
LID - 10.1038/ajg.2016.481 [doi]
AB  - OBJECTIVES: Multiple studies have reported an association between proton pump 
      inhibitor (PPI) use and fracture. However, the causality of this association is 
      questionable, as there is not a well defined mechanism of action, nor is there 
      evidence of an effect on PPIs on areal bone mineral density (aBMD) using dual 
      photon X-ray absorptiometry (DXA). It is possible that PPIs may induce changes in 
      bone structure which would predispose to fracture in the absence of changes in 
      aBMD. We used three-dimensional quantitative computed tomography (3D-QCT) imaging 
      to determine if long-term PPI use was associated with structural changes in bone 
      independent of aBMD. METHODS: We enrolled a sample of long-term (>/=5 years) PPI 
      users matched to a similar cohort of persons with no PPI use in the previous 5 
      years. All subjects underwent assessment of aBMD using DXA, volumetric BMD using 
      3D-QCT, as well as markers of bone metabolism. Measures of bone strength, 
      including buckling ratio and section modulus, were also compared between the two 
      samples. RESULTS: 104 subjects were enrolled (52 PPI users and 52 PPI non-users). 
      There were no differences detected in standard BMD, volumetric BMD, markers of 
      bone metabolism or measures of bone strength between the two groups. CONCLUSIONS: 
      Long-term PPI use is not associated with any changes in bone mineral density or 
      bone strength that would predispose to an increased risk of fracture. These 
      findings provide further evidence that the association between PPI use and 
      fracture is not causal.
FAU - Targownik, Laura E
AU  - Targownik LE
AD  - Section of Gastroenterology, Department of Internal Medicine, University of 
      Manitoba, Winnipeg, Manitoba, Canada.
AD  - Manitoba Inflammatory Bowel Disease Research Centre, Winnipeg, Manitoba, Canada.
FAU - Goertzen, Andrew L
AU  - Goertzen AL
AD  - Department of Radiology, University of Manitoba, Winnipeg, Manitoba, Canada.
AD  - Section of Nuclear Medicine, Health Sciences Centre, Winnipeg, Manitoba, Canada.
FAU - Luo, Yunhua
AU  - Luo Y
AD  - Department of Mechanical Engineering, University of Manitoba, Winnipeg, Manitoba, 
      Canada.
AD  - Graduate Program in Biomedical Engineering, University of Manitoba, Winnipeg, 
      Manitoba, Canada.
FAU - Leslie, William D
AU  - Leslie WD
AD  - Department of Radiology, University of Manitoba, Winnipeg, Manitoba, Canada.
AD  - Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, 
      Canada.
LA  - eng
GR  - CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20161115
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - 0 (Collagen Type I)
RN  - 0 (Gastrins)
RN  - 0 (Parathyroid Hormone)
RN  - 0 (Peptides)
RN  - 0 (Phosphates)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (collagen type I trimeric cross-linked peptide)
RN  - 104982-03-8 (Osteocalcin)
RN  - 1406-16-2 (Vitamin D)
RN  - A288AR3C9H (25-hydroxyvitamin D)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - I38ZP9992A (Magnesium)
RN  - SY7Q814VUP (Calcium)
SB  - IM
CIN - Am J Gastroenterol. 2017 Apr;112(4):651. PMID: 28381836
CIN - Am J Gastroenterol. 2017 Apr;112(4):651-652. PMID: 28381844
MH  - Absorptiometry, Photon
MH  - Aged
MH  - Alkaline Phosphatase/metabolism
MH  - *Bone Density
MH  - Bone Diseases, Metabolic/diagnostic imaging/epidemiology/metabolism
MH  - Bone and Bones/diagnostic imaging/metabolism
MH  - Calcium/metabolism
MH  - Cohort Studies
MH  - Collagen Type I/metabolism
MH  - Female
MH  - Femur Neck/*diagnostic imaging/metabolism
MH  - Gastrins/metabolism
MH  - Humans
MH  - Imaging, Three-Dimensional
MH  - Linear Models
MH  - Magnesium/metabolism
MH  - Male
MH  - Manitoba/epidemiology
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Osteocalcin/metabolism
MH  - Osteoporosis/diagnostic imaging/*epidemiology/metabolism
MH  - Parathyroid Hormone/metabolism
MH  - Peptides/metabolism
MH  - Phosphates/metabolism
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Time Factors
MH  - Tomography, X-Ray Computed
MH  - Vitamin D/analogs & derivatives/metabolism
EDAT- 2016/11/16 06:00
MHDA- 2017/06/21 06:00
CRDT- 2016/11/16 06:00
PHST- 2016/04/01 00:00 [received]
PHST- 2016/07/04 00:00 [revised]
PHST- 2016/07/02 00:00 [accepted]
PHST- 2016/11/16 06:00 [pubmed]
PHST- 2017/06/21 06:00 [medline]
PHST- 2016/11/16 06:00 [entrez]
AID - ajg2016481 [pii]
AID - 10.1038/ajg.2016.481 [doi]
PST - ppublish
SO  - Am J Gastroenterol. 2017 Jan;112(1):95-101. doi: 10.1038/ajg.2016.481. Epub 2016 
      Nov 15.